1460902339-ee7582ad-66e6-4a4c-913f-9a11fbef200c

1. A null-fill antenna comprising:
a first antenna array including antenna elements arranged with a prescribed point as the center; and
a second antenna array with an excitation amplitude substantially equal to or less than that of the antenna elements forming the first antenna array; wherein:
the first antenna array is excited so that the excitation amplitude distribution is to have symmetry with respect to the prescribed point, while the excitation phase distribution is to have substantially point symmetry with respect to the prescribed point; and
the phase center of the first antenna array is substantially coincident with that of the second antenna array,
wherein, among the antenna elements forming the first antenna array, antenna elements on one side of the phase center are advanced more in excitation phase as the distance from the phase center increases, while antenna elements on the other side of the phase center are delayed more in excitation phase as the distance from the phase center increases.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound having the general structure shown in Formula I:
wherein:
R1 is H, OR8, NR9R10 , or CHR9R10, wherein R8, R9 and R10 can be the same or different, each being independently selected from the group consisting of H, alkyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, cycloalkyl-, arylalkyl-, and heteroarylalkyl;
E and J can be the same or different, each being independently selected from the group consisting of R, OR, NHR, NRR7, SR, halo, and S(O2)R, or E and J can be directly connected to each other to form either a three to eight-membered cycloalkyl, or a three to eight-membered heterocyclyl moiety;
Z is N(H), N(R), or O;
G is C(\u2550O) or S(O2), with the proviso that when Z is O, G is not S(O2);
Y is selected from the group consisting of:
R, R7, R2, R3, R4 and R5 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl-, (cycloalkyl)alkyl-, (heterocyclyl)alkyl-, aryl-alkyl-, and heteroaryl-alkyl-, wherein each of said heteroalkyl, heteroaryl and heterocyclyl independently has one to six oxygen, nitrogen, sulfur, or phosphorus atoms;

wherein each of said alkyl, heteroalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl and heterocyclyl moieties can be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclyl, halo, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, carboxylic acid, carbamate, urea, ketone, aldehyde, cyano, nitro, sulfonamido, sulfoxide, sulfone, sulfonyl urea, hydrazide, and hydroxamate.
2. The compound of claim 1, wherein R2 is selected from the group consisting of the following moieties:
3. The compound of claim 1, wherein R3 is selected from the group consisting of:
wherein R31 is OH or O-alkyl; and
R32 is H, C(O)CH3, C(O)OtBu or C(O)N(H)tBu.
4. The compound of claim 3, wherein R3 is selected from the group consisting of:
5. The compound of claim 1, wherein
is selected from the group consisting of:
wherein
Y31 is selected from the group consisting of: OR, NHR and NRR7 and
Y32 is selected from the group consisting of:
6. The compound of claim 1, wherein Z is NH.
7. The compound of claim 1, wherein Z is N(R).
8. The compound of claim 1, wherein Z is OG is C(\u2550O).
9. The compound of claim 1, wherein G is present and is C(\u2550O) or S(O2).
10. The compound of claim 1, wherein Y is selected from the group consisting of:
11. The compound of claim 1, wherein:
is selected from the group consisting of:
12. A pharmaceutical composition comprising as an active ingredient at least one compound of claim 1.
13. The pharmaceutical composition of claim 12 for use in treating disorders associated with HCV.
14. The pharmaceutical composition of claim 12 additionally comprising at least one pharmaceutically acceptable carrier.
15. The pharmaceutical composition of claim 14, additionally containing at least one antiviral agent.
16. The pharmaceutical composition of claim 15, still additionally containing at least one interferon.
17. The pharmaceutical composition of claim 16, wherein said at least one antiviral agent is ribavirin and said at least one interferon is \u03b1-interferon or pegylated interferon.
18. A method of treating disorders associated with the HCV, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of at least one compound of claim 1.
19. The method of claim 18, wherein said administration is oral or subcutaneous.
20. A method of preparing a pharmaceutical composition for treating the disorders associated with the HCV, said method comprising bringing into intimate contact at least one compound of claim 1 and at least one pharmaceutically acceptable carrier.
21. A compound exhibiting HCV protease inhibitory activity, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound being selected from the compounds of structures listed below:
22. A compound, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound being selected from the compounds of structures listed below:
23. A pharmaceutical composition for treating disorders associated with the HCV, said composition comprising therapeutically effective amount of one or more compounds in claim 22 and a pharmaceutically acceptable carrier.
24. The pharmaceutical composition of claim 23, additionally containing at least one antiviral agent.
25. The pharmaceutical composition of claim 24, still additionally containing at least one interferon or PEG-interferon alpha conjugate.
26. The pharmaceutical composition of claim 25, wherein said at least one antiviral agent is ribavirin and said at least one interferon is \u03b1-interferon or pegylated interferon.
27. A method of treatment of a hepatitis C virus associated disorder, comprising administering an effective amount of one or more compounds of claim 22.
28. A method of modulating the activity of hepatitis C virus (HCV) protease, comprising contacting HCV protease with one or more compounds of claim 22.
29. A method of treating or ameliorating one or more symptoms of hepatitis C (HCV), comprising administering a therapeutically effective amount of one or more compounds of claim 22.
30. The method of claim 29, wherein the HCV protease is the NS3NS4a protease.
31. The method of claim 29, wherein the compound or compounds inhibit HCV NS3NS4a protease.
32. A method of modulating the processing of hepatitis C virus (HCV) polypeptide, comprising contacting a composition containing the HCV polypeptide under conditions in which said polypeptide is processed with one or more compounds of claim 22.
33. A compound of claim 1 in purified form.
34. A compound, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates of said compound, or a pharmaceutically acceptable salt, solvate or ester of said compound, said compound having the general structure shown in Formula I:
wherein:
R1 is NR9R10, and R9 is H, R10 is H or R14, wherein R14 is alkyl, aryl, heteroalkyl, heteroaryl, cycloalkyl, alkyl-aryl-, alkyl-heteroaryl-, aryl-alkyl-, alkenyl, alkynyl or heteroaryl-alkyl-;
E and J can be the same or different, each being independently selected from the group consisting of R, OR, NHR, NRR7, SR halo, and S(O2)R, or E and J can be directly connected to each other to form either a three to eight-membered cycloalkyl, or a three to eight-membered heterocyclyl moiety;
Z is N(H), N(R), or O, G is C(\u2550O) or S(O2) with the proviso that when Z is O, G is not S(O2) and;
Y is selected from the group consisting of
R, R7, R2, R3, R4 and R5 can be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl-, (cyclcoalkyl)alkyl-, (heterocyclyl)alkyl-, aryl-alkyl-, and heteroaryl-alkyl-, wherein each of said heteroalkyl, heteroaryl and heterocyclyl independently has one to six oxygen, nitrogen, sulfur, or phosphorus atoms;